Glucose Regulation — Insulin, Glucagon and the Pancreatic Feedback System
Every cell in your body runs on glucose. Too much and blood vessels corrode. Too little and neurons die within minutes. The pancreas runs a continuous two-hormone balancing act to keep blood glucose within a 4–6 mmol/L window — and when that system fails, it produces the most common chronic disease in Australia.
Download this lesson's worksheet
Use the PDF for classwork, homework or revision. It includes key ideas, activities, questions, an extend task and success-criteria proof.
Endocrine System
Why Doesn't Blood Glucose Crash During Exercise?
When you sprint 400 metres, your leg muscles burn through glucose at a rate roughly 20 times higher than at rest. Your blood only contains about 5 grams of dissolved glucose at any moment — enough to fuel about 30 seconds of sprinting at that rate.
Yet in a healthy person, blood glucose during a 400 m sprint barely drops below 4 mmol/L. It might dip slightly, then stabilise — and within minutes of finishing, it returns to normal.
Before reading on, answer these two questions:
Q1: If muscles are consuming glucose faster than you are eating, where is the replacement glucose coming from? Name the organ you think is most likely involved.
Q2: After a large meal, blood glucose could rise to 8–10 mmol/L if nothing corrected it. What do you think the body does with that excess glucose, and which hormone do you think is involved?
Know
- The role of alpha cells (glucagon) and beta cells (insulin) in the islets of Langerhans
- The complete pathway for responding to high blood glucose (insulin pathway)
- The complete pathway for responding to low blood glucose (glucagon pathway)
- The role of the liver in glycogenesis and glycogenolysis
- The difference between Type 1 and Type 2 diabetes at the mechanism level
Understand
- Why the pancreas must run two opposing hormones simultaneously to maintain fine control
- Why the liver — not the pancreas — is the primary effector in glucose regulation
- Why Type 1 and Type 2 diabetes are fundamentally different diseases despite similar symptoms
- How failure of glucose homeostasis produces the specific complications of diabetes
Can Do
- Draw and label the complete insulin and glucagon feedback pathways from stimulus to response
- Identify insulin, glucagon, glycogenesis, and glycogenolysis in an exam scenario
- Distinguish Type 1 from Type 2 diabetes using mechanism-level language
- Apply the stimulus-response model to a glucose regulation scenario
Connect this concept back to the broader homeostasis and disease framework you have built across the course.
The Pancreas — Receptor and Control Centre Combined
In the temperature regulation system (L02), the receptor (thermoreceptors) and the control centre (hypothalamus) were separate structures. Glucose regulation is slightly different — the pancreatic islet cells function as both receptor and effector in the same organ, detecting blood glucose directly and secreting the corrective hormone without a separate signal processing step.
Glucose regulation feedback loop showing insulin and glucagon action
Comparison of Type 1 and Type 2 diabetes
The pancreas is a dual-function organ: most of it is exocrine (secreting digestive enzymes into the small intestine), but scattered throughout the tissue are roughly one million small clusters of endocrine cells called the Islets of Langerhans. Two cell types in the islets are critical for glucose homeostasis:
- Beta cells detect rising blood glucose concentrations and secrete insulin directly into the bloodstream. They are simultaneously the receptor (they sense glucose) and the secretory unit (they release the hormone).
- Alpha cells detect falling blood glucose concentrations and secrete glucagon directly into the bloodstream. They operate in opposition to beta cells.
Both hormones travel through the blood to their primary target: the liver. This makes the liver the key effector in glucose homeostasis — it is the organ that actually changes blood glucose concentration in response to these hormonal signals. The liver can act as a glucose sink (storing excess as glycogen during high blood glucose) and a glucose source (releasing stored glucose during low blood glucose).
Simulate blood glucose and insulin levels after meals, exercise, and fasting. Watch how the graph changes with each event and observe the negative feedback pattern that keeps glucose within the tolerance range.
After a meal, blood glucose rises → insulin is released → glucose falls. During exercise or fasting, glucose drops → glucagon is released → glucose rises. This push-pull system maintains blood glucose around the 5 mmol/L set point.
The Two Feedback Pathways — High Glucose and Low Glucose
Glucose homeostasis is maintained by two opposing negative feedback loops that operate simultaneously — one activated when glucose is too high, one when it is too low. Together they produce continuous oscillation around the set point of approximately 5 mmol/L.
When Blood Glucose Is HIGH (e.g. after a meal)
Stimulus: blood glucose rises above ~6 mmol/L
Beta cells in islets of Langerhans detect high glucose → secrete insulin into bloodstream
Insulin travels to body cells → cells increase uptake of glucose (GLUT4 transporters move to membrane)
Insulin travels to liver → liver converts glucose to glycogen (glycogenesis) and stores it
Blood glucose falls back toward ~5 mmol/L → beta cells detect normalisation → insulin secretion decreases (self-limiting negative feedback)
When Blood Glucose Is LOW (e.g. during exercise, fasting)
Stimulus: blood glucose falls below ~4 mmol/L
Alpha cells in islets of Langerhans detect low glucose → secrete glucagon into bloodstream
Glucagon travels to the liver → liver breaks down stored glycogen to glucose (glycogenolysis)
Glucose released from liver into the bloodstream → blood glucose rises toward ~5 mmol/L
Alpha cells detect normalising glucose → glucagon secretion decreases (self-limiting negative feedback)
Why two hormones instead of one?
A single hormone that simply 'corrected' glucose would create sluggish control — the response would lag too far behind the stimulus, resulting in large swings. Two opposing hormones provide faster, more precise fine-tuning: as blood glucose rises from a meal, insulin rises rapidly; before glucose has fully fallen back to the set point, glucagon is already suppressed. This push-pull system maintains tighter oscillation than a single-hormone system could achieve.
This is analogous to how a car's cruise control uses both throttle and brake simultaneously to maintain a steady speed on varying terrain — not just one input in response to deviation.
Drag the glucose slider to see how insulin and glucagon work as opposing hormones to maintain the glucose set point. Observe which pancreatic cells activate and what the liver does in response to each hormone.
Beta cells release insulin when glucose is high, promoting glucose uptake by liver, muscle, and adipose tissue. Alpha cells release glucagon when glucose is low, triggering glycogenolysis in the liver. The liver is the key effector that physically changes blood glucose concentration.
The Liver — The Key Effector in Glucose Homeostasis
The pancreatic islet cells detect and signal — but the liver is the structure that physically changes blood glucose concentration. Without a functioning liver, neither insulin nor glucagon can maintain blood glucose homeostasis regardless of how much hormone is present.
The liver receives blood directly from the gastrointestinal tract via the portal vein, making it the first organ to encounter glucose absorbed from digested food. This positioning is not coincidental — it allows the liver to act as a first-pass buffer, absorbing a large fraction of post-meal glucose before it reaches systemic circulation.
Glycogenesis — storing glucose when insulin is high
When insulin levels are elevated (post-meal), the liver converts excess blood glucose into glycogen — a branched polymer of glucose that can be compactly stored. A healthy liver can store approximately 100 g of glycogen, equivalent to roughly 400 kcal. This stored glycogen is the rapid-release glucose reserve that prevents hypoglycaemia during fasting or exercise.
Glycogenolysis — releasing glucose when glucagon is high
When glucagon levels are elevated (fasting, exercise), the liver breaks down stored glycogen back into glucose and releases it into the bloodstream. This process can sustain blood glucose for approximately 12–16 hours of fasting — after which the liver begins gluconeogenesis (synthesising new glucose from amino acids and glycerol), but that is beyond the scope of this lesson.
Why the answer to Think First Q1 is the liver
During a 400 m sprint, blood glucose dips slightly, triggering glucagon release. The liver immediately begins glycogenolysis — releasing stored glucose into the blood. This is why blood glucose stays stable: the liver is continuously releasing glucose to match the rate at which muscles are consuming it. The liver is not making new glucose — it is releasing its stored glycogen. This is why athletes 'carb load' before endurance events: they are maximising liver (and muscle) glycogen stores to delay glucose depletion.
Reorder the steps of the glucose homeostasis pathway into the correct sequence. This tests your understanding of the complete negative feedback loop from stimulus to response.
The glucose homeostasis pathway follows a clear sequence: detect change → release hormone → act on effector → return to set point. Both high and low glucose scenarios use the same stimulus-response framework with different hormones and effector actions.
When Glucose Homeostasis Fails — Type 1 and Type 2 Diabetes
Diabetes mellitus is the collective name for conditions in which blood glucose homeostasis fails — either because insulin cannot be produced, or because target cells no longer respond to it adequately. Both outcomes produce chronic hyperglycaemia, but the underlying mechanism and therefore the treatment approach differ fundamentally.
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Primary cause | Autoimmune destruction of pancreatic beta cells → no insulin produced | Insulin resistance in target cells → inadequate glucose uptake despite insulin present |
| Insulin levels | Very low or absent | Initially normal or high; beta cells may eventually exhaust and decline |
| Which part of pathway fails | Step 2 — beta cells cannot secrete insulin (no hormone) | Step 3 — cells do not respond to insulin (no response to hormone) |
| Homeostatic consequence | High blood glucose cannot be corrected — chronic hyperglycaemia | High blood glucose inadequately corrected — chronic hyperglycaemia |
| Age of typical onset | Often childhood or adolescence (but can occur at any age) | Typically adult onset (but increasingly adolescent) |
| Risk factors | Genetic predisposition; autoimmune triggers | Obesity, physical inactivity, diet, genetic predisposition, age |
| Management | Insulin injections or pump (cannot be managed without exogenous insulin) | Lifestyle modification, metformin, other medications; insulin only in late stages |
Why chronic hyperglycaemia causes complications
When blood glucose remains chronically elevated above ~7 mmol/L, glucose molecules attach non-enzymatically to proteins throughout the body — a process called glycation. Glycated proteins in blood vessel walls cause them to thicken and lose elasticity, progressively narrowing capillaries. This vascular damage produces the characteristic long-term complications of diabetes: retinopathy (damage to retinal blood vessels → blindness), nephropathy (damage to glomerular capillaries → kidney failure), neuropathy (damage to nerve supply capillaries → loss of sensation, particularly in feet), and accelerated cardiovascular disease.
All of these complications follow from a single homeostatic failure — chronic blood glucose exceeding the tolerance range — which is why early detection and blood glucose management are the central goals of diabetes care.
Wearing a Feedback System Outside the Body
A continuous glucose monitor (CGM) is a small device worn on the arm or abdomen by people with diabetes. A tiny sensor sits just beneath the skin and measures interstitial glucose concentration every 5 minutes, sending the data wirelessly to a smartphone app. When blood glucose rises above a set threshold, the app alerts the user to take insulin. When it falls below a lower threshold, it alerts them to consume carbohydrate.
In effect, the CGM is replacing the receptor and control centre functions that the islets of Langerhans can no longer perform adequately — constantly monitoring the key homeostatic variable and triggering a corrective response when it deviates. The human (or in closed-loop 'artificial pancreas' systems, an automated insulin pump) acts as the effector.
This technology directly maps onto the stimulus-response model from L01: CGM sensor = receptor; algorithm/app = control centre; insulin pump or human decision = effector; insulin injection or carbohydrate intake = response. Understanding the biology of glucose homeostasis allows you to understand exactly what each component of the technology is doing and why.
Priority Misconceptions — Glucose Regulation
"Glucagon breaks down glucose." — Glucagon triggers glycogenolysis — the breakdown of glycogen (stored polymer) into glucose. Glucagon does not act on blood glucose directly; it acts on liver cells, signalling them to hydrolyse glycogen. The end result is more glucose in the blood, but glucagon does not break down glucose molecules.
"Insulin is produced by alpha cells." — Insulin is produced by beta cells. Glucagon is produced by alpha cells. This is consistently reversed by students. The two words begin with the same syllable — use the cue: Beta cells, Blood glucose too high, Bring it down (insulin).
"Type 1 and Type 2 diabetes are the same disease — just different severity." — They are mechanistically distinct. Type 1 = no insulin produced (beta cell destruction). Type 2 = insulin produced but cells don't respond (insulin resistance). A Type 2 diabetic with intact beta cells and insulin resistance cannot be treated with lifestyle alone if insulin resistance is severe — but they still have functioning beta cells. A Type 1 diabetic has no beta cell function at all and cannot survive without exogenous insulin.
"The pancreas is the effector in glucose homeostasis." — The pancreas is primarily the receptor and signalling gland. The liver is the key effector — it is the organ that physically changes blood glucose concentration through glycogenesis and glycogenolysis. Muscle cells are also effectors (they take up glucose under insulin's influence), but the liver is the primary one examined in HSC Biology.
"Insulin 'destroys' excess blood glucose." — Insulin does not destroy glucose. It signals cells to take up glucose (for immediate use in respiration) and signals the liver to convert glucose to glycogen for storage. The glucose is either used or stored — never destroyed.
Image Slot 1: Annotated diagram showing the two-pathway glucose regulation system — pancreas with alpha cells (glucagon arrow pointing to liver → glycogenolysis → glucose released) and beta cells (insulin arrow pointing to body cells + liver → glucose uptake + glycogenesis) — with blood glucose rising and falling curves shown alongside, and negative feedback arrows looping back to pancreas.
Image Slot 2: Side-by-side diagrams comparing Type 1 diabetes (beta cells absent/destroyed, no insulin produced, blood glucose remains high) and Type 2 diabetes (insulin present but receptor on cell does not respond, blood glucose remains high despite insulin signal). Labelled to show exactly which step of the pathway fails in each case.